Natural History of Patients With PH3 and a History of Stone Events (PHYOX-OBX)
A Natural History Study of Patients With Genetically Confirmed Primary Hyperoxaluria Type 3 and, as Applicable Per Age, a History of Stone Events
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Listed as NCT04542590, this observational or N/A phase trial focuses on Primary Hyperoxaluria Type 3 and remains completed. Sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, it has been updated 15 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Dec 2024 — Present [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Oct 2024 — Dec 2024 [monthly]
Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting
▶ Show 10 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting
-
Jan 2024 — Apr 2024 [monthly]
Active Not Recruiting
Status: Enrolling By Invitation → Active Not Recruiting
-
Sep 2023 — Jan 2024 [monthly]
Enrolling By Invitation
Status: Recruiting → Enrolling By Invitation
-
May 2023 — Sep 2023 [monthly]
Recruiting
-
Dec 2021 — May 2023 [monthly]
Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Not Yet Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
For direct contact, visit the study record on ClinicalTrials.gov .